认知障碍与肌缩性侧面硬化症的步态变化和跌倒风险有关
Raffaele Dubbioso1, Myriam Spisto1,2, Jeffrey M Hausdorff3,4,5,6
1Department of Neurosciences, Reproductive Sciences and Odontostomatology, University Federico II of Naples, Naples, Italy.
European journal of neurology
|June 19, 2023
概括
肌缩性侧面硬化 (ALS) 中的轻度认知障碍 (MCI) 与增加的步态变异性有关,并预测未来的跌倒. 这凸显了认知评估在治疗ALS患者和预防跌倒方面的重要性.
科学领域:
- 神经学 神经学
- 生物医学工程 生物医学工程
- 老年学是一门学科.
背景情况:
- 肌缩侧面硬化症 (ALS) 的特点是走路异常,增加跌倒风险.
- 以前对ALS的步态研究忽视了认知方面,主要关注运动缺陷.
研究的目的:
- 为了研究ALS患者的步态模式,包括轻度认知障碍 (MCI) 和没有轻度认知障碍 (MCI).
- 确定ALS的认知状态,步态变化和跌倒发生之间的关系.
- 为了在单一和双重任务条件下比较步态.
主要方法:
- 可穿戴的步态分析设备用于评估门诊ALS患者 (MCI+和MCI-) 和健康受试者 (HS).
- 步行参数测量在正常行走 (单任务) 和倒数 (双任务) 的过程中.
- 在评估后的3个月内,记录了跌倒的发生率和数量,并与认知功能相关联.
主要成果:
- 无论认知状态如何,ALS患者的步态变化比HS患者更大.
- 双重任务揭示了ALS MCI+和ALS MCI-组之间步行变化 (节奏,姿势/摆动时间,稳定性) 的显著差异.
- 与ALS MCI患者和HS患者相比,ALS MCI+患者的发病率和跌倒次数较高.
- 轻度认知障碍和执行功能障碍预测未来的跌倒,独立于运动障碍.
结论:
- 在ALS中,轻度认知障碍与步态变异性增加有关.
- 认知障碍,特别是MCI,是ALS患者短期下降的重要预测因素.
- 将认知评估整合到ALS护理中可能会改善跌倒预防策略.
相关概念视频
Alzheimer's Disease: Overview
532
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
532
Parkinson's Disease: Overview
611
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
611


